JP2017514917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514917A5 JP2017514917A5 JP2017510766A JP2017510766A JP2017514917A5 JP 2017514917 A5 JP2017514917 A5 JP 2017514917A5 JP 2017510766 A JP2017510766 A JP 2017510766A JP 2017510766 A JP2017510766 A JP 2017510766A JP 2017514917 A5 JP2017514917 A5 JP 2017514917A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- eye
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 14
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 12
- 208000002780 macular degeneration Diseases 0.000 claims description 12
- 208000030533 eye disease Diseases 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007943 implant Substances 0.000 claims description 7
- 206010023332 keratitis Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 206010010741 Conjunctivitis Diseases 0.000 claims description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
- 206010013774 Dry eye Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 210000001508 eye Anatomy 0.000 claims description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 4
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 claims description 4
- 206010015943 Eye inflammation Diseases 0.000 claims description 4
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 claims description 4
- 210000005252 bulbus oculi Anatomy 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000003889 eye drop Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 4
- 208000020911 optic nerve disease Diseases 0.000 claims description 4
- 210000003786 sclera Anatomy 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- -1 haloalkanyloxy Chemical group 0.000 description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 17
- 125000003342 alkenyl group Chemical group 0.000 description 14
- 229910005965 SO 2 Inorganic materials 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 125000000262 haloalkenyl group Chemical group 0.000 description 8
- 125000000232 haloalkynyl group Chemical group 0.000 description 8
- 125000004423 acyloxy group Chemical group 0.000 description 6
- 125000003302 alkenyloxy group Chemical group 0.000 description 6
- 125000005133 alkynyloxy group Chemical group 0.000 description 6
- 125000005291 haloalkenyloxy group Chemical group 0.000 description 5
- 125000005292 haloalkynyloxy group Chemical group 0.000 description 5
- 125000006323 alkenyl amino group Chemical group 0.000 description 4
- 125000005108 alkenylthio group Chemical group 0.000 description 4
- 125000005109 alkynylthio group Chemical group 0.000 description 4
- 125000005014 aminoalkynyl group Chemical group 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 125000006319 alkynyl amino group Chemical group 0.000 description 3
- 125000005021 aminoalkenyl group Chemical group 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 3
- 125000005016 hydroxyalkynyl group Chemical group 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 0 C*C(C(CC(C1)=C)=C1C(Nc(c(C)c(C)c(-c1cc(OC(C)(F)F)ccc1)c1F)c1F)=O)=O Chemical compound C*C(C(CC(C1)=C)=C1C(Nc(c(C)c(C)c(-c1cc(OC(C)(F)F)ccc1)c1F)c1F)=O)=O 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- OMPATGZMNFWVOH-UHFFFAOYSA-N COc1cccc(-c(cc2F)cc(F)c2Nc(nccc2)c2C(O)=O)c1 Chemical compound COc1cccc(-c(cc2F)cc(F)c2Nc(nccc2)c2C(O)=O)c1 OMPATGZMNFWVOH-UHFFFAOYSA-N 0.000 description 1
- UXXPWPXXEGXERY-CYBMUJFWSA-N C[C@H](CC(C(CCC1)=C1C(O)=O)=O)c(cc1)cc(F)c1OCc(c(Cl)ccc1)c1I Chemical compound C[C@H](CC(C(CCC1)=C1C(O)=O)=O)c(cc1)cc(F)c1OCc(c(Cl)ccc1)c1I UXXPWPXXEGXERY-CYBMUJFWSA-N 0.000 description 1
- PVWLYLAEVRTJCY-UHFFFAOYSA-N Cc1cc(Nc(ccc(C2CC2)c2)c2C(O)=O)cnc1-c1cc(OC(F)(F)F)ccc1 Chemical compound Cc1cc(Nc(ccc(C2CC2)c2)c2C(O)=O)cnc1-c1cc(OC(F)(F)F)ccc1 PVWLYLAEVRTJCY-UHFFFAOYSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167490.3 | 2014-05-08 | ||
| EP14167490 | 2014-05-08 | ||
| EP14170616 | 2014-05-30 | ||
| EP14170616.8 | 2014-05-30 | ||
| PCT/EP2015/060166 WO2015169944A1 (en) | 2014-05-08 | 2015-05-08 | Compounds for treating ophthalmic diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514917A JP2017514917A (ja) | 2017-06-08 |
| JP2017514917A5 true JP2017514917A5 (enExample) | 2018-06-21 |
| JP6629840B2 JP6629840B2 (ja) | 2020-01-15 |
Family
ID=53051826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510766A Expired - Fee Related JP6629840B2 (ja) | 2014-05-08 | 2015-05-08 | 眼の疾患および障害を処置するための化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11730716B2 (enExample) |
| EP (1) | EP3139914B1 (enExample) |
| JP (1) | JP6629840B2 (enExample) |
| KR (1) | KR102312186B1 (enExample) |
| CN (2) | CN116077665A (enExample) |
| AU (1) | AU2015257651B2 (enExample) |
| BR (1) | BR112016025997A8 (enExample) |
| CA (1) | CA2947067C (enExample) |
| CL (1) | CL2016002812A1 (enExample) |
| ES (1) | ES2960598T3 (enExample) |
| HK (1) | HK1231417A1 (enExample) |
| IL (1) | IL248732B (enExample) |
| MX (1) | MX378707B (enExample) |
| NZ (1) | NZ725574A (enExample) |
| PL (1) | PL3139914T3 (enExample) |
| SG (1) | SG11201608835VA (enExample) |
| WO (1) | WO2015169944A1 (enExample) |
| ZA (1) | ZA201607260B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| JP6629840B2 (ja) * | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| KR20170091157A (ko) | 2014-12-23 | 2017-08-08 | 4디 파마 리서치 리미티드 | 피린 폴리펩티드 및 면역 조정 |
| PL3065748T3 (pl) | 2014-12-23 | 2018-07-31 | 4D Pharma Research Limited | Szczep Bacteroides thetaiotaomicron i jego zastosowanie w zmniejszaniu zapalenia |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| SI3240554T1 (sl) | 2015-06-15 | 2019-12-31 | 4D Pharma Research Limited, | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni |
| EA201890050A1 (ru) | 2015-06-15 | 2018-06-29 | 4Д Фарма Рисёрч Лимитед | Композиции, содержащие бактериальные штаммы |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MD3650033T2 (ro) | 2015-06-15 | 2022-08-31 | 4D Pharma Res Ltd | Compoziții conţinând tulpini bacteriene |
| AU2016357554B2 (en) | 2015-11-20 | 2019-04-04 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| JP6961879B2 (ja) * | 2015-12-30 | 2021-11-05 | レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| EP3520801A1 (en) | 2016-03-04 | 2019-08-07 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
| TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| IL270066B2 (en) | 2017-04-24 | 2023-10-01 | Aurigene Oncology Ltd | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| JP7212945B2 (ja) | 2017-05-22 | 2023-01-26 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| MD3804737T2 (ro) | 2017-06-14 | 2022-10-31 | 4D Pharma Res Limited | Compoziții care conțin tulpini bacteriene |
| WO2018229188A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| CN115813955A (zh) | 2017-06-14 | 2023-03-21 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| JPWO2018230713A1 (ja) * | 2017-06-16 | 2020-04-16 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| CN110944668A (zh) | 2017-06-16 | 2020-03-31 | 学校法人同志社 | 用于治疗或预防眼部症状、障碍或疾病的包含mTOR抑制剂的药物及其应用 |
| KR102861339B1 (ko) | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| WO2019170848A1 (en) | 2018-03-09 | 2019-09-12 | Panoptes Pharma Ges.M.B.H. | Ophthalmic formulation |
| WO2019175396A1 (en) * | 2018-03-16 | 2019-09-19 | Immunic Ag | Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| JP2021519334A (ja) | 2018-03-26 | 2021-08-10 | クリア クリーク バイオ， インコーポレイテッド | ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法 |
| US20210300873A1 (en) | 2020-03-20 | 2021-09-30 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
| WO2021216548A1 (en) * | 2020-04-21 | 2021-10-28 | University Of Massachusetts | Methods and compositions for treatment of age-related macular degeneration |
| CN111638341A (zh) * | 2020-07-01 | 2020-09-08 | 山东凯歌智能机器有限公司 | 一种检测小细胞肺癌患者外周血循环肿瘤细胞pd-l1基因突变的试剂盒及检测方法 |
| EP4228640A1 (en) * | 2020-10-15 | 2023-08-23 | ASLAN Pharmaceuticals Pte Ltd | Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor |
| BR112023020806A2 (pt) | 2021-04-09 | 2023-12-12 | Immunic Ag | Inibidores de dhodh deuterados |
| UY40087A (es) * | 2021-12-23 | 2023-06-30 | Immunic Ag | Inhibidores de DHODH que contienen un bioisóstero de ácido carboxílico. |
| AU2023228646A1 (en) * | 2022-03-01 | 2024-09-19 | Kiora Pharmaceuticals Gmbh | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor |
| CN119300819A (zh) * | 2022-03-09 | 2025-01-10 | 克奥拉制药股份有限公司 | 二氢乳清酸脱氢酶（dhod）抑制剂的多晶型物 |
| WO2024138064A1 (en) * | 2022-12-22 | 2024-06-27 | Cavalry Biosciences, Inc. | Compositions and methods for treating meibomain gland dysfunction |
| TW202506107A (zh) | 2023-06-28 | 2025-02-16 | 德商埃慕尼克股份公司 | 雜芳族dhodh抑制劑 |
| WO2026074007A1 (en) | 2024-10-02 | 2026-04-09 | Immunic Ag | Nurr1 agonists with replacement of the carboxylic acid or carboxamide moiety for use in the treatment of neurodegenerative diseases |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61103836A (ja) | 1984-10-24 | 1986-05-22 | Green Cross Corp:The | フイブロネクチン製剤 |
| DD297328A5 (de) * | 1989-08-18 | 1992-01-09 | �������@���������k���Kk�� | 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen |
| EP0834320B1 (en) | 1996-04-19 | 2004-09-01 | R-Tech Ueno, Ltd. | Albumin as active ingredient for treating corneal and conjunctival lesion and dry eye |
| HUP9701554D0 (en) | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| WO2003006424A1 (en) | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| AU2003301347A1 (en) * | 2002-10-17 | 2004-05-04 | Control Delivery Systems, Inc. | Methods for monitoring treatment of disease |
| US7365094B2 (en) | 2002-12-23 | 2008-04-29 | 4Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| US7071355B2 (en) * | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2004056747A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| DE60330391D1 (de) * | 2002-12-23 | 2010-01-14 | 4Sc Ag | Cycloalken-dicarbonsäure-verbindungen als entzündungshemmende, immunmodulatorische und antiproliferative mittel |
| US7714132B2 (en) | 2004-03-11 | 2010-05-11 | Actelion Pharmaceuticals, Ltd. | Tetrahydropyridoindole derivatives |
| JP2006089485A (ja) * | 2004-08-24 | 2006-04-06 | Santen Pharmaceut Co Ltd | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| WO2007038687A2 (en) * | 2005-09-27 | 2007-04-05 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
| ES2319596B1 (es) * | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| JP2009270356A (ja) | 2008-05-08 | 2009-11-19 | Yoshinobu Hayashi | アスベスト含有被覆層剥ぎ取り物の処理方法 |
| TWI530286B (zh) | 2009-05-04 | 2016-04-21 | 帕納特斯製藥格斯有限公司 | 作為抑制病毒化合物之抗發炎劑 |
| US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
| US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| RS60051B1 (sr) * | 2011-06-10 | 2020-04-30 | Ramscor Inc | Formulacije sa produženim oslobađanjem za isporuku proteina u oko i postupci njihove pripreme |
| KR102265277B1 (ko) * | 2014-04-11 | 2021-06-16 | 판옵테스 파르마 게스.엠.베.하. | 바이러스 억제 화합물로서의 항-염증제 |
| JP6629840B2 (ja) * | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| JP6961879B2 (ja) | 2015-12-30 | 2021-11-05 | レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
| WO2019170848A1 (en) | 2018-03-09 | 2019-09-12 | Panoptes Pharma Ges.M.B.H. | Ophthalmic formulation |
| BR112023020806A2 (pt) | 2021-04-09 | 2023-12-12 | Immunic Ag | Inibidores de dhodh deuterados |
| AU2023228646A1 (en) | 2022-03-01 | 2024-09-19 | Kiora Pharmaceuticals Gmbh | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor |
| CN119300819A (zh) | 2022-03-09 | 2025-01-10 | 克奥拉制药股份有限公司 | 二氢乳清酸脱氢酶（dhod）抑制剂的多晶型物 |
-
2015
- 2015-05-08 JP JP2017510766A patent/JP6629840B2/ja not_active Expired - Fee Related
- 2015-05-08 WO PCT/EP2015/060166 patent/WO2015169944A1/en not_active Ceased
- 2015-05-08 BR BR112016025997A patent/BR112016025997A8/pt not_active Application Discontinuation
- 2015-05-08 KR KR1020167033322A patent/KR102312186B1/ko active Active
- 2015-05-08 MX MX2016014634A patent/MX378707B/es unknown
- 2015-05-08 CA CA2947067A patent/CA2947067C/en active Active
- 2015-05-08 NZ NZ725574A patent/NZ725574A/en unknown
- 2015-05-08 EP EP15720340.7A patent/EP3139914B1/en active Active
- 2015-05-08 CN CN202310101659.5A patent/CN116077665A/zh active Pending
- 2015-05-08 CN CN201580036856.7A patent/CN106572968A/zh active Pending
- 2015-05-08 SG SG11201608835VA patent/SG11201608835VA/en unknown
- 2015-05-08 PL PL15720340.7T patent/PL3139914T3/pl unknown
- 2015-05-08 HK HK17105296.1A patent/HK1231417A1/zh unknown
- 2015-05-08 AU AU2015257651A patent/AU2015257651B2/en active Active
- 2015-05-08 ES ES15720340T patent/ES2960598T3/es active Active
- 2015-05-08 US US15/309,176 patent/US11730716B2/en active Active
-
2016
- 2016-10-20 ZA ZA2016/07260A patent/ZA201607260B/en unknown
- 2016-11-03 IL IL248732A patent/IL248732B/en active IP Right Grant
- 2016-11-07 CL CL2016002812A patent/CL2016002812A1/es unknown
-
2023
- 2023-03-23 US US18/189,010 patent/US12364680B2/en active Active
-
2025
- 2025-06-24 US US19/248,216 patent/US20250381167A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6629840B2 (ja) | 眼の疾患および障害を処置するための化合物 | |
| CA2806942C (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
| US20110117189A1 (en) | Ophthalmic compositions for treating pathologies of the posterior segment of the eye | |
| JP2020530470A (ja) | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 | |
| US20220072015A1 (en) | Methods of Inhibiting Pathological Angiogenesis | |
| CN107708738B (zh) | 含有柠檬酸酯的贮库制剂 | |
| JP2025107451A (ja) | 緑内障を治療するためのＷｎｔ５ａの調節 | |
| US20210113529A1 (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| ES2672099T3 (es) | Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal | |
| JP6267003B2 (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| JP2023543498A5 (enExample) | ||
| JP6928479B2 (ja) | 拒絶反応抑制剤 | |
| Cornel et al. | Novelties in medical treatment of glaucoma | |
| HK40104751A (zh) | 治疗青光眼的wnt5a的调节 | |
| CN117355292A (zh) | 用于预防或治疗眼病的抑制n-氧代吡啶化合物出现的眼科组合物 | |
| CN116515827A (zh) | 用于治疗年龄相关性黄斑变性的活性成分、药物组合物和应用 | |
| HK40107693A (zh) | 用於退行性视网膜疾病的trpa1通道拮抗剂化合物 | |
| HK40035073A (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability |